연구성과로 돌아가기
2023 연구성과별 연구자 정보 (69 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Seo, Seyoung | Seo, S | 1 | Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea | sbkim3@amc.seoul.kr; | |||||
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Keam, Bhumsuk | Keam, B | 2 | Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea | sbkim3@amc.seoul.kr; | |||||
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Shin, Seong Hoon | Shin, SH | 3 | Kosin Univ, Dept Internal Med, Gospel Hosp, Busan, South Korea | sbkim3@amc.seoul.kr; | |||||
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Chae, Yee Soo | Chae, YS | 4 | Kyungpook Natl Univ, Dept Oncol Hematol, Med Ctr Biobank, Daegu, South Korea | sbkim3@amc.seoul.kr; | |||||
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Kim, Tae Min | Kim, TM | 5 | Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea | B-9921-2013 | Kim, Tae | 0000-0001-6145-4426 | Kim, Tae Min | sbkim3@amc.seoul.kr; | |
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Park, Lee Chun | Park, LC | 6 | Kosin Univ, Dept Internal Med, Gospel Hosp, Busan, South Korea | sbkim3@amc.seoul.kr; | |||||
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Hong, Seung-Beom | Hong, SB | 7 | ISU ABXIS Co Ltd, Res Ctr, Seongnam, South Korea | sbkim3@amc.seoul.kr; | |||||
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Ahn, Myung-Ju | Ahn, MJ | 8 | Sungkyunkwan Univ, Samsung Med Ctr, Dept Hematol Oncol, Sch Med, Seoul, South Korea | sbkim3@amc.seoul.kr; | |||||
| A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer | Kim, Sung-Bae | Kim, SB | 9 | 교신저자 | Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea | JXL-8219-2024 | Kim, Sung-Bae | sbkim3@amc.seoul.kr; | ||
| A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) | Lim, M. C. | Lim, MC | 1 | NCC Natl Canc Ctr, Gynecol Canc Ctr, Goyang Si, South Korea | ||||||
| A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) | Kim, Ji Hyun | Kim, JH | 1 | Natl Canc Ctr, Ctr Gynecol Canc, Goyang, South Korea | E-2279-2012 | Kim, Joon | ||||
| A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) | Kim, J. H. | Kim, JH | 2 | NCC Natl Canc Ctr, Gynecol Canc Ctr, Goyang Si, South Korea | ||||||
| A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) | Park, Boram | Park, B | 2 | Samsung Med Ctr, Res Inst Future Med, Biomed Stat Ctr, Seoul, South Korea | ||||||
| A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) | Park, B. | Park, B | 3 | Samsung Med Ctr, Res Inst Future Med, Biomed Stat Ctr, Seoul, South Korea | ABB-2937-2021 | Park, Sun | ||||
| A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) | Park, Jeong-Yeol | Park, JY | 3 | Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea | W-5046-2019 | Park, Jeong-Yeol |
페이지 이동: